Amanda
Lopez Picado
Instituto de Salud Carlos III
Madrid, EspañaPublikationen in Zusammenarbeit mit Forschern von Instituto de Salud Carlos III (2)
2021
-
Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial
The Lancet, Vol. 398, Núm. 10295, pp. 121-130
-
Socio-Demographic Health Determinants Are Associated with Poor Prognosis in Spanish Patients Hospitalized with COVID-19
Journal of General Internal Medicine, Vol. 36, Núm. 12, pp. 3737-3742